Back to Search
Start Over
Phase I evaluation of AT-125 single dose every three weeks.
- Source :
-
Investigational new drugs [Invest New Drugs] 1984; Vol. 2 (3), pp. 311-4. - Publication Year :
- 1984
-
Abstract
- A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.
- Subjects :
- Adult
Aged
Antibiotics, Antineoplastic administration & dosage
Central Nervous System drug effects
Drug Administration Schedule
Drug Evaluation
Glutamine antagonists & inhibitors
Humans
Isoxazoles administration & dosage
Middle Aged
Neoplasms drug therapy
Antibiotics, Antineoplastic adverse effects
Isoxazoles adverse effects
Oxazoles adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 0167-6997
- Volume :
- 2
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Investigational new drugs
- Publication Type :
- Academic Journal
- Accession number :
- 6511237
- Full Text :
- https://doi.org/10.1007/BF00175382